NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced today that Dr. Irach Taraporewala, Chief Executive Officer of Ohr Pharmaceutical, will be presenting at the 15 th Annual BIO CEO and Investor 2013 conference, taking place at the Waldorf Astoria Hotel in New York City on February 11-12, 2013. Dr. Taraporewala's presentation will include an overview of Ohr's clinical wet-AMD eye drop program and ongoing phase II clinical trial, the OHR/AVR118 Phase II cancer cachexia trial, and the Company's business outlook and expected milestones for 2013.
Details of the presentation are as follows: Presentation Day: Monday, February 11 Time: 4:30 pm EST Room: Duke of Windsor Room, 4 th Floor
The presentation will be webcast live and available for replay for 90 days using the following link (Webcast) or on the investor page of our corporate website.
About Ohr Pharmaceutical Inc. Ohr Pharmaceutical Inc. (OTCQB:OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The company is focused on two lead compounds currently being investigated in clinical phase II trials: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the company can be found at www.ohrpharmaceutical.com.About BIO CEO 2013 The BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason. Contact: Ohr Pharmaceutical Inc. Investor Relations: Tel: (877) 215-4813Email: firstname.lastname@example.org